The Danish biotech company, Tetra Pharm Technologies, is launching its first product, XATEPA, on the German market. XATEPA is a pain-relieving pharmaceutical drug based on cannabinoids.
Tetra Pharm Technologies develops and manufactures pharmaceutical drugs targeting the endocannabinoid system for the treatment of neuropathic pain, sclerosis and mental health disorders.
"The launch of our first product represents an important and significant milestone for Tetra Pharm Technologies. From a business perspective, it gives us the opportunity to further strengthen the company's long-term research and development efforts, which is our primary focus", stated Martin Rose, CEO, Tetra Pharm Technologies.
Tetra Pharm Technologies plans to expand sales of XATEPA and launch the drug in a number of additional European and overseas markets in the near future.
"The suitability of the drug delivery system is often neglected at the expense of cannabinoid bioavailability. Our XATEPA sublingual spray is devised as a so-called enabling technology to provide optimal conditions for cannabinoid uptake and thus efficacy. From a pharmaceutical science perspective, we are indeed very proud of this achievement, and we look forward to launch more innovative products targeting the endocannabinoid system", stated Dr. Morten Allesø, chief scientific officer, Tetra Pharm Technologies.
Tetra Pharm Technologies has entered into an agreement with PHOENIX Pharma-Einkauf GmbH for the distribution of XATEPA in Germany.
"Germany is the largest market in Europe for pharmaceutical drugs based on cannabinoids, and we have positive expectations for the sales of XATEPA. The partnership with PHOENIX Pharma-Einkauf GmbH regarding distribution to German pharmacies ensures access to the product for all doctors and their patients, and since we have eliminated any middlemen, we can deliver the product at a fair price", stated Martin Caspersen, chief commercial officer, Tetra Pharm Technologies.
Photo by Esteban López on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!